Dyadic Attends Investor Events in December
November 30, 2023 08:30 ET
|
Dyadic International, Inc.
Dyadic Attends Investor Events in December
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
November 29, 2023 08:30 ET
|
Dyadic International, Inc.
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
November 27, 2023 21:00 ET
|
AIM ImmunoTech Inc.
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 28, 2023 ...
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
November 27, 2023 09:05 ET
|
AIM ImmunoTech Inc.
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 27, 2023 ...
AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
November 21, 2023 12:00 ET
|
AIM ImmunoTech Inc.
No severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”)...
AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update
November 15, 2023 07:30 ET
|
AIM ImmunoTech Inc.
– Highlights continued execution across Ampligen® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will...
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
November 09, 2023 08:05 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss...
Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 08, 2023 16:00 ET
|
Dyadic International, Inc.
Received an upfront payment of $0.6 million in October for product development and licensing of our Dapibus™ platform for animal-free dairy enzyme productsDYAI-100 Phase 1 clinical trial top-line...
Japan's WAFUU.COM: 20-Language Global Expansion, 1200%+ Growth
November 01, 2023 11:00 ET
|
Qrestia Inc.
Japan's WAFUU.COM has started offering curated Japanese goods, now providing global shipping and multi-language support to share Japan's allure worldwide.
Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19
October 26, 2023 06:45 ET
|
BioNTech SE
Lead formulations evaluated in the Phase 1/2 study demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains Safety profile of the mRNA-based combination vaccine...